List of Excipients in Branded Drug OMEGAVEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Fresenius Kabi USA LLC	OMEGAVEN	fish oil	63323-205	.ALPHA.-TOCOPHEROL, DL-	2026-07-30
Fresenius Kabi USA LLC	OMEGAVEN	fish oil	63323-205	EGG PHOSPHOLIPIDS	2026-07-30
Fresenius Kabi USA LLC	OMEGAVEN	fish oil	63323-205	GLYCERIN	2026-07-30
Fresenius Kabi USA LLC	OMEGAVEN	fish oil	63323-205	SODIUM HYDROXIDE	2026-07-30
Fresenius Kabi USA LLC	OMEGAVEN	fish oil	63323-205	SODIUM OLEATE	2026-07-30
Fresenius Kabi USA LLC	OMEGAVEN	fish oil	63323-205	WATER	2026-07-30

OMEGAVEN Excipient Strategy, Patent Protection, and Commercial Opportunities

Last updated: August 18, 2026

Omegaven is a prescription intravenous fish-oil lipid emulsion containing omega-3-acid triglycerides. Its commercial position depends less on a conventional small-molecule patent franchise than on formulation complexity, sterile manufacturing, supply-chain control, regulatory exclusivity, and clinical familiarity in parenteral nutrition-associated cholestasis. The principal commercial opportunities are differentiated ready-to-use bags, alternative container systems, improved emulsion stability, hospital supply contracts, adult parenteral-nutrition applications, and competing omega-3 lipid emulsions.

What is Omegaven and what excipients does it contain?

Omegaven is an intravenous lipid emulsion indicated as a source of calories and fatty acids for pediatric patients with parenteral nutrition-associated cholestasis, or PNAC. It contains 10 g of fish-oil-derived omega-3-acid triglycerides per 100 mL, equivalent to a 10% lipid emulsion. The product is manufactured by Fresenius Kabi USA, LLC and was approved by the FDA in 2018 under NDA 210589.[1,2]

Component	Function in Omegaven
Omega-3-acid triglycerides	Active lipid and caloric source
Egg phospholipids	Primary emulsifier
Glycerin	Tonicity and osmotic adjustment
Sodium oleate	Emulsion stabilization and pH control support
Water for injection	Continuous aqueous phase

The FDA label identifies egg phospholipids, glycerin, sodium oleate, and water for injection as inactive ingredients.[1] The formulation has a pH range of approximately 6.0 to 9.5 and is designed for intravenous administration after dilution or admixture with parenteral nutrition components under controlled conditions.

How does the Omegaven excipient system affect commercial performance?

The excipient system is central to product quality because Omegaven is a sterile oil-in-water emulsion. The formulation must maintain droplet-size control, prevent creaming or coalescence, preserve sterility, and remain compatible with amino acids, dextrose, electrolytes, vitamins, and other parenteral nutrition components.

Egg phospholipids

Egg phospholipids provide the interfacial film around oil droplets. Their quality attributes include:

• Phospholipid composition
• Source and purity of egg material
• Peroxide and oxidation levels
• Residual proteins and allergenic impurities
• Batch-to-batch interfacial performance

Egg-derived emulsifiers create a potential supply and regulatory constraint. A manufacturer developing a competing product would need to demonstrate that any alternative emulsifier provides equivalent physical stability, toxicological acceptability, and clinical performance.

Potential substitutes include purified soybean phospholipids, synthetic phospholipids, or mixed phospholipid systems. Each alternative could change droplet-size distribution, oxidation behavior, compatibility, and immunologic risk. Substitution would generally require a new formulation-development program rather than a simple excipient replacement.

Glycerin

Glycerin adjusts tonicity and contributes to the product's osmolality. Its concentration must remain compatible with intravenous administration and the final parenteral nutrition admixture. Glycerin is readily available and is unlikely to create a material patent barrier. Its commercial value lies in process control, grade selection, and supply qualification rather than exclusivity.

Sodium oleate

Sodium oleate supports emulsion stability and may influence pH and interfacial behavior. It is used at a low concentration, but small changes can affect droplet stability and interaction with other admixture components. A competing formulation could avoid sodium oleate, but the alternative would require comparative stability data.

Water for injection

Water for injection is the aqueous vehicle. Its supply is commoditized, but sterile manufacturing capacity, endotoxin control, container closure integrity, and validated filling operations remain important barriers.

What formulation attributes are protected by Omegaven's product design?

The most defensible protection for Omegaven is likely the integrated formulation and manufacturing process rather than an easily copied list of excipients.

Relevant technical attributes include:

1. A 10% fish-oil lipid concentration.
2. Omega-3-acid triglyceride composition.
3. Egg-phospholipid emulsification.
4. Controlled particle-size distribution.
5. Sterile manufacturing and terminal or aseptic processing.
6. Oxidation control for highly unsaturated fatty acids.
7. Compatibility with parenteral nutrition admixtures.
8. Container and closure systems that limit oxygen exposure.
9. Labeling and dosing protocols for pediatric PNAC.

Fish oil contains highly unsaturated fatty acids that are vulnerable to oxidation. A commercially viable competitor would need controls for dissolved oxygen, headspace oxygen, light exposure, peroxide formation, and storage temperature. These controls can create manufacturing know-how even when the excipient list is public.

How strong is the Omegaven patent estate?

Omegaven's market protection has been driven primarily by regulatory exclusivity and formulation complexity, not by a widely recognized composition-of-matter patent comparable to a conventional small-molecule drug.

Protection category	Omegaven relevance
Composition-of-matter patent	No broadly recognized active-ingredient patent is associated with fish-oil triglycerides
Formulation patents	Potentially relevant for emulsion composition, stability, particle size, and oxidation control
Manufacturing patents	Potentially relevant for sterile processing, mixing, oxygen control, and filling
Method-of-use patents	Potentially relevant to PNAC treatment and pediatric parenteral nutrition
FDA orphan exclusivity	Material historical protection for the approved rare pediatric indication
Generic pathway	505(j) ANDA pathway is more relevant than a biosimilar pathway

The active lipid mixture is a natural-source or naturally derived product rather than a novel synthetic molecular entity. That limits the value of traditional composition patents. Patent strength therefore depends on whether claims cover a sufficiently narrow formulation or process while still capturing commercial competitors.

Formulation claims can be vulnerable to design-around strategies. A competitor may alter the phospholipid source, oil concentration, antioxidant system, container, or manufacturing sequence. Narrow claims may be difficult to enforce if a competing product uses a different emulsifier or stability profile.

When did Omegaven lose or approach exclusivity?

Omegaven received FDA approval on July 27, 2018, for pediatric PNAC.[2] It was approved for a rare disease indication and received orphan-drug exclusivity. The standard orphan exclusivity period is seven years from approval, subject to the statutory scope of the protected indication.[3]

Milestone	Date or period
FDA approval	July 27, 2018
NDA	210589
Orphan exclusivity period	Approximately through July 2025
Relevant generic opportunity	After applicable regulatory exclusivity and subject to patent barriers
Current commercial assessment	Exclusivity-based protection has materially weakened; technical and manufacturing barriers remain

Orphan exclusivity does not block every product for every use. It restricts FDA approval of the same drug for the same orphan indication unless statutory exceptions apply. It also does not create a permanent monopoly over fish-oil emulsions or all PNAC uses.

What is the Orange Book status of Omegaven?

Omegaven is an NDA product and can be evaluated through the FDA Orange Book framework. The Orange Book is the controlling source for listed patents and approved drug-product information.[4]

The key diligence questions are:

• Whether NDA 210589 has listed patents.
• Whether any listed patent covers the formulation, method of use, or delivery system.
• Whether any listed patent has expired.
• Whether a generic applicant could submit a Paragraph IV certification.
• Whether pediatric PNAC labeling remains protected independently of the product formulation.

Omegaven does not have a conventional small-molecule active-ingredient patent position. Any listed patent protection would be more likely to concern formulation or method-of-use claims. For generic entry, the commercial significance of those patents would depend on claim breadth, enforceability, and whether an ANDA applicant can use a non-infringing formulation or a section viii labeling carve-out.

Which companies could challenge Omegaven through an ANDA?

Omegaven is not a biologic, so biosimilar competition is not the applicable pathway. A potential competitor would generally pursue an abbreviated new drug application if it could establish pharmaceutical equivalence and therapeutic equivalence to the reference product.

Likely competitor profiles include:

• Generic injectable manufacturers with lipid-emulsion capability.
• Contract manufacturers with sterile emulsion capacity.
• Existing parenteral nutrition suppliers.
• Companies commercializing omega-3 injectable emulsions outside the United States.
• Hospital-compounding organizations seeking standardized commercial products.

A Paragraph IV challenge would be relevant only if Omegaven had an unexpired Orange Book-listed patent. The challenge would typically allege that the patent is invalid, unenforceable, or not infringed. The commercial timing would depend on the ANDA filing date, patent litigation, 30-month stay exposure, and the scope of any settlement.

No major public Omegaven Paragraph IV litigation or settlement is identified in the core FDA materials cited here. That does not eliminate future litigation risk; it indicates that the main competitive question is likely technical equivalence and manufacturing economics rather than an established litigation record.

What generic entry risks exist for Omegaven?

Generic entry risk is moderate from a technical perspective and higher over the long term as orphan exclusivity protection recedes.

Technical barriers

An injectable lipid emulsion is more difficult to copy than a tablet because the applicant must control:

• Mean droplet diameter
• Large-diameter tail particles
• Emulsion separation
• Sterility and endotoxin levels
• Oxidative degradation
• Container interaction
• In-use stability
• Admixture compatibility
• Product performance after dilution

The FDA has recognized that complex formulations may require more extensive pharmaceutical equivalence testing than conventional immediate-release products.[5]

Commercial barriers

The market is concentrated among hospitals, pediatric intensive-care units, neonatal centers, and parenteral nutrition providers. A generic must offer reliable supply, competitive pricing, validated admixture compatibility, and pharmacy support. A low-price entrant may struggle if it lacks sterile manufacturing scale or faces high quality-control costs.

What commercial opportunities exist for Omegaven-like excipients?

Excipient substitution

A competing product could pursue a lower-cost or more secure emulsifier strategy. Synthetic phospholipids could reduce dependence on egg-derived materials, although they may increase raw-material cost and regulatory-development requirements.

Potential value propositions include:

• Reduced allergenic impurity risk
• Lower oxidation rates
• Better lot-to-lot consistency
• Improved compatibility with neonatal nutrition systems
• Reduced dependence on animal-derived materials

Antioxidant systems

The approved formulation does not rely on a prominent, separately marketed antioxidant excipient strategy in the way some injectable products use alpha-tocopherol or other oxidation-control systems. A competitor could investigate antioxidants, oxygen scavenging, nitrogen headspace, or light-protective packaging. Any change would require careful evaluation because antioxidant systems can affect safety, color, compatibility, and regulatory comparability.

Container and delivery technology

Commercial opportunities include:

• Low-oxygen multilayer bags
• Light-protective overwraps
• Smaller pediatric dose presentations
• Ready-to-use admixture bags
• Unit-dose pharmacy formats
• Closed-system transfer compatibility
• Improved hang-time and in-use stability

Packaging improvements can create differentiation even where the active lipid composition is similar.

Adult parenteral nutrition

Omegaven's U.S. indication is pediatric PNAC, but omega-3 lipid emulsions have broader clinical relevance in parenteral nutrition. An adult-focused product could target intestinal failure, home parenteral nutrition, critical care, and liver dysfunction. A new indication would require clinical and regulatory support and could create method-of-use patent opportunities.

Hospital and supply-chain contracts

The product category is suitable for value-based procurement. Buyers may prioritize:

• Shortage resilience
• Predictable delivery
• Reduced pharmacy preparation
• Lower waste
• Stable pricing
• Compatibility with existing nutrition protocols

A manufacturer with dual-source phospholipids, redundant fish-oil suppliers, and domestic sterile filling could compete effectively without owning a strong patent estate.

How does Omegaven compare with other lipid emulsions?

Product category	Principal lipid source	Typical strategic position
Omegaven	Fish-oil-derived omega-3 triglycerides	Omega-3-focused pediatric PNAC product
Soybean-oil emulsions	Soybean oil	Conventional parenteral lipid nutrition
Mixed-oil emulsions	Soybean, olive, coconut, and fish oils	Broader fatty-acid profile and formulation differentiation
Pure fish-oil competitors	Fish oil	Direct clinical and commercial competition
Custom compounded emulsions	Variable	Lower standardization and higher pharmacy burden

Omegaven's strongest differentiator is its fish-oil lipid composition and FDA-approved pediatric PNAC indication. Its weaknesses are a narrow labeled indication, exposure to fish-oil and phospholipid supply constraints, and the absence of a clearly dominant active-ingredient patent barrier.

What licensing deals and manufacturing barriers affect Omegaven?

The principal commercial manufacturer is Fresenius Kabi. No major public licensing transaction is identified in the FDA approval materials reviewed for this analysis. The key manufacturing barriers are:

• Qualified fish-oil raw-material supply
• Control of oxidation during storage and processing
• Sterile emulsion scale-up
• High-pressure homogenization or equivalent particle-size control
• Aseptic filling
• Container closure integrity
• Stability testing over the labeled shelf life
• Regulatory validation of admixture compatibility

Fish-oil sourcing can introduce geographic and seasonal variability. Supply agreements should address fatty-acid specifications, contaminant testing, oxidation limits, traceability, and alternative suppliers. Manufacturers may gain practical protection through validated processes, qualified suppliers, and hospital contracts even where patent protection is limited.

What revenue exposure and launch scenarios are most relevant?

Omegaven revenue is concentrated in specialized hospital settings rather than broad retail pharmacy. The highest-value customers are pediatric hospitals, neonatal intensive-care units, intestinal-failure programs, and parenteral nutrition pharmacies.

Scenario	Commercial effect
No direct generic	Continued premium pricing, with procurement pressure
One approved generic	Price erosion and hospital formulary competition
Multiple injectable competitors	Material price compression and contract rebidding
Supply disruption	Short-term pricing power for reliable suppliers
Adult indication expansion	Larger addressable market and new clinical investment
Improved ready-to-use presentation	Premium opportunity through labor and waste reduction

A first entrant with reliable sterile manufacturing could capture share even without a major patent challenge. The product's clinical niche and hospital purchasing dynamics make supply reliability a material competitive asset.

Key Takeaways

• Omegaven is a 10% intravenous fish-oil lipid emulsion approved in 2018 for pediatric PNAC.
• Its key excipients are egg phospholipids, glycerin, sodium oleate, and water for injection.
• Egg phospholipids are the most strategically important excipient because they control emulsion performance and create sourcing and allergen-management considerations.
• The product's protection is more dependent on orphan exclusivity, formulation know-how, sterile manufacturing, and supply control than on a novel active-ingredient patent.
• Omegaven's approximately seven-year orphan exclusivity period ran from July 2018 to about July 2025.
• Generic competition would proceed through the ANDA pathway, not the biosimilar pathway.
• Direct formulation competition faces meaningful technical barriers involving droplet size, oxidation, sterility, and admixture compatibility.
• The most attractive commercial opportunities are alternative emulsifier systems, antioxidant and oxygen-control strategies, low-oxygen packaging, ready-to-use pediatric formats, adult PN applications, and reliable hospital supply.

FAQs

Is Omegaven a biologic drug?

No. Omegaven is a sterile lipid emulsion regulated as an NDA drug. A competing product would generally pursue an ANDA where the regulatory requirements can be met.

Can egg phospholipids in Omegaven be replaced?

Potentially, but substitution would require redevelopment and testing of emulsion stability, toxicity, compatibility, particle size, and manufacturing performance.

Does Omegaven have biosimilar competition?

No. Biosimilar competition applies to biologics. Omegaven's relevant competitive pathway is generic injectable competition.

What is the most valuable Omegaven excipient innovation?

The highest-value opportunity is likely a phospholipid and oxygen-control system that improves oxidative stability, reduces sourcing risk, and preserves compatibility with parenteral nutrition admixtures.

Can a competitor sell an omega-3 lipid emulsion for adults without infringing Omegaven rights?

Potentially. Adult use, a different formulation, or a different labeled indication could reduce exposure to pediatric method-of-use claims, but regulatory approval and any applicable patent claims must be assessed independently.

References

1. U.S. Food and Drug Administration. (2023). Omegaven prescribing information. Fresenius Kabi USA, LLC.

2. U.S. Food and Drug Administration. (2018, July 27). Approval letter for NDA 210589: Omegaven.

3. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. U.S. Food and Drug Administration. (2022). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development